nonsevere relapsing EGPA who are receiving glucocorticoid monotherapy, starting mepolizumab would be preferred over adding methotrexate, azathioprine, or mycophenolate mofetil, given the treatment's proven efficacy in this population in a randomized trial Recommendation: For patients with EGPA and high serum IgE levels who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we